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Abstract
To get beyond the ‘‘low-hanging fruits’’ so far identified by genome-wide association (GWA) studies, new methods must be
developed in order to discover the numerous remaining genes that estimates of heritability indicate should be contributing to
complex human phenotypes, such as obesity. Here we describe a novel integrative method for complex disease gene identification
utilizing both genome-wide transcript profiling of adipose tissue samples and consequent analysis of genome-wide association data
generated in large SNP scans. We infer causality of genes with obesity by employing a unique set of monozygotic twin pairs
discordant for BMI (n=13pairs, age 24–28 years, 15.4 kgmeanweight difference) and contrast the transcript profileswith those from
a larger sample of non-related adult individuals (N=77). Using this approach, wewere able to identify 27 genes with possibly causal
roles in determining the degree of human adiposity. Testing for association of SNP variants in these 27 genes in the population
samples of the large ENGAGE consortium (N=21,000) revealed a significant deviation of P-values from the expected (P=461024). A
total of 13 genes contained SNPs nominally associated with BMI. The top finding was blood coagulation factor F13A1 identified as a
novel obesity gene also replicated in a second GWA set of,2,000 individuals. This study presents a new approach to utilizing gene
expression studies for informing choice of candidate genes for complex human phenotypes, such as obesity.
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Introduction
In the current age of genome-wide association (GWA) studies
using hundreds of thousands of single nucleotide polymorphisms
(SNPs), obesity has been a popular phenotype to investigate.
Obesity, often measured as the body mass index (BMI) and
defined as BMI$30 kg/m2, is important not only because of high
and increasing prevalence, its strong association to many clinical
complications such as type 2 diabetes, but also for the relative ease
and availability of phenotypic measurement in most studies of
human health. The heritability of BMI in twin and adoption
studies range from 45%–85% [1] and still substantial, though
somewhat lower in family studies. There are rare Mendelian
syndromes with associated obesity and insights from rodent models
and many linkage studies of obesity have identified chromosomal
regions possibly harboring obesity genes on all chromosomes
except the Y chromosome [2]. However, the known mutations
account for only a small fraction of severe, early onset obesity and
virtually none of the variability in adult overweight and obesity,
while linkage studies and candidate gene studies have been
plagued by a lack of replication [2]. Even meta-analyses of linkage
have failed to reveal new genes.
The advent of GWA studies of BMI has lead to novel, robust
findings. However, the genes identified so far have been able to
explain only a small fraction of the variation in BMI; FTO, the first
gene unequivocally associated with BMI was estimated to explain
,1% of the total variance in the discovery sample set [3]. That
study involved the genotyping of more than 30,000 individuals and
the identification of the next most convincing, common BMI
associated gene MC4R required the combined analysis of more
than 77,000 individuals [4]. The most recent results from the
GIANT Consortium with more than 91,000 analyzed DNA
samples were able to identify an additional six new loci for BMI,
together explaining 0.40% of the total variance in BMI [5].
Significantly, these six new loci in conjunction with the known
associations at FTO and MC4R only accounted for 0.84% of the
total variance [5], an observation that highlights the ‘‘winner’s
curse’’ phenomenon whereby effect sizes of associated variants are
often exaggerated in the initial study relative to follow-up studies
[6]. A simultaneous publication reported similar findings in a
study consisting largely of the Icelandic DeCode data set. There,
four loci identified in the GIANT consortium study and seven new
loci influencing BMI were uncovered (each with explanatory
power comparable to the variants from the GIANT consortium
study) [7].
Even if only a fraction of the observed heritability of BMI
consists of genes with universal effects in most, if not all
populations, the remaining obesity predisposing genes surely
number in the hundreds, if not thousands. However, their
individual contributions are expected to be increasingly more
modest and as such, more difficult to identify by (now)
conventional means of GWA. The uncovering of these remaining
genes will either call for unrealistically large sample sizes, or
rather, novel methods for nominating potential candidate genes
likely to be causally involved with the trait of interest.
The integration of genome-wide expression data from relevant
tissues with SNP scans is a promising approach for identifying
novel genes involved in the development of complex disease traits
such as obesity. Microarray data and SNP scans from individuals
have been combined in order to map variants (eQTLs) that
control the expression of nearby genes in segregating populations
[8,9]. While these studies have identified large numbers of cis-
acting variants and a smaller number of trans-acting variants, they
are not powered to link the changes in gene expression with the
development of complex diseases and their trait components.
Correlation of gene expression with a phenotype such as BMI
however does not imply causation and the difficulty comes in
discerning the transcripts that merely react to the disease state in
target tissues from those that are actually related to causal
processes. This is an especially challenging task in human studies,
where the system cannot be perturbed in the same sense as is
possible with animal models or cell lines. In order to circumvent
some of these challenges and to infer causality, we studied adipose
tissue gene expression in a unique collection of young monozygotic
twin pairs without other co-morbidities discordant for BMI [n = 13
pairs, age 24–28 years, 15.4 kg mean weight difference, with no
significant height differences (,3 cm)] as well as in a set of 77
unrelated individuals in order to establish a set of genes most likely
to be related to causal processes in controlling the degree of
human adiposity. Given that monozygotic twins are identical at
the level of DNA sequence (precluding somatic mutations),
differences in the expression of the genes encoded therein are
the result of regulatory and/or epigenetic changes in response to
lifestyle and the environment. By this logic, the genes with
significant expression differences in the adipose tissue between the
lean and obese monozygotic co-twins in discordant pairs can be
designated as reactive to the obesity. In contrast, genes whose
transcript levels in adipose tissue correlate significantly with BMI
in a large sample of non-related individuals will be a mixture of
reactive genes as well as genes related to causal processes. While it
would be expected that there would be a significant degree of
overlap in the list of genes identified in the two different sample
sets, the subset of genes that correlate significantly with BMI
only in the non-related sample would present as candidates for
primarily being related to causal processes. Genes identified as
possibly ‘‘causal’’ to obesity can subsequently be interrogated for
association with BMI in a large GWA study cohort in order
to establish whether the genes harbor sequence variants that
effect their expression in cis. This study design is presented in
Figure 1.
Results
MZ twin pairs discordant for BMI
The precise effects of acquired obesity have been difficult to
investigate due to the complex interaction of genes and the
environment that are thought to be involved in its development.
The correlation of BMI as measured between pairs of genetically
identical twins representative of the population is very high, with a
correlation coefficient of 0.79 in the FinnTwin16 study from which
the twins here analyzed were recruited [10]. It is the rare cases of
significantly discordant twin pairs that allows for the most detailed
analysis of the environmental effects, in this case of acquired obesity.
With the MZ co-twin control design applied here, we were able to
control for gender, age, cohort effects as well as other exposures and
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experiences of childhood that are shared by siblings in a family.
Thus, we carefully assess the effects that obesity has on the
transcription of genes in adipose tissue.
A thorough description of these 13 pairs of MZ twins (age 24–28
years, eight male pairs and six female pairs) most discordant for
BMI has been published earlier by our group [11]. Briefly, the
selected pairs represent 5% extreme ends in divergence of
phenotypes and the obese co-twins were on average 15.4 kg
(22%) heavier than the lean co-twin. They exhibited a significantly
larger fat mass in every depot measured, including subcutaneous,
intra-abdominal and liver fat (P,0.002). Consequently the obese
twins were also much more insulin resistant, as evidenced by the
lower M-value and higher fasting serum insulin levels. Obesity in
the heavier co-twins had developed after post-pubertal adoles-
cence [12] and thus the metabolic abnormalities represent
consequences of early stages of excess adiposity (Table S1).
Sample of unrelated individuals
The sample of unrelated individuals used consisted of 77 individuals
from the same Finnish population as the MZ twins. Subjects had been
recruited as a part of a large study on familial dyslipidemias and
consisted of 41 women and 36 men. Phenotypic measures (61S.D.)
were as follows: BMI 26.664.1 kg/m2 (range 20.1–37.8 kg/m2), age
at adipose tissue biopsy 51611.6 years (range 27.4–68.9 years). They
thus exhibit a wide and representative range of BMI.
Gene expression changes related to increased adiposity
First, in order to establish the list of genes most likely to be
‘‘reactive’’ to the obese state, samples of subcutaneous adipose
tissue from the discordant MZ twins were analyzed. Following co-
twin normalization of the expression data, we identified 2,674
transcripts differentially regulated in the adipose tissue of the obese
twins compared to that of the lean co-twin (non-parametric Welch
t-test, using a liberal test value, i.e. P,0.05).
Next, in a data set consisting of adipose tissue samples from 77
unrelated individuals, using stringent criteria (Pearson correlation
P,1024) we identified 84 transcripts that correlated with BMI.
Of these, 56 (or 2/3) were shared with those identified in MZ
study samples and designated as ‘‘reactive’’. The remaining 28
transcripts encoded by 27 unique genes that, while strongly
correlated with BMI, were not differentially regulated in the
discordant MZ twins and as such were candidates for being related
to causal processes (Table 1). The P-value for the Pearson
correlation between BMI and gene expression for these genes in
the unrelated sample ranged from 2.561026 for HADHA, to
9.9961025 for SAP30BP. By definition, these genes were not
differentially expressed between the obese and lean co-twins (P-
values 0.35 and 0.56 respectively). The P-values for correlation of
expression level with BMI among the twins ranged from 0.051 to
0.849. A number of the known obesity associated genes were not
included in the analyses, as they were filtered out either as reactive
(Leptin), showed no significant correlation with BMI in either
sample (FTO), or were not expressed in fat (MC4R).
Mining the ENGAGE consortium GWA data
In order to assess, whether any of the genes identified as
putatively causative in influencing obesity also harbored SNP
variants associated with the trait, we employed the large
ENGAGE consortium study sample consisting of more than
21,000 GWA scans from well characterized European population
cohorts, not ascertained for any specific trait. An analysis of the
197 SNPs, -representing the 27 putatively ‘‘causative’’ genes
revealed a significant excess of small P-values, differing from the
expected uniform distribution (X2 P-value 461024). By contrast,
the 498 SNPs representing the 48 genes ‘‘reactive’’ to obesity did
no better than expected by chance (X2 P-value 0.59), as witnessed
by the Q-Q plots with very different profiles for the two gene sets
(Figure 2). It is possible for such Q-Q plots to be inflated due to a
large number of associating SNPs in one or a few genes (with high
local LD), but re-drawing these plots while retaining only the best
single SNP per gene did not significantly change their profiles
(Figure S1).
Out of the 27 tested putatively causative genes, 13 genes
harbored a total of 23 SNPs that were nominally associated with
BMI in our sample (P,0.05) (Table 2). The top hit was SNP
rs2274393 (P= 0.003) located in an intron of the 177 kb gene
encoding the A1 subunit of the coagulation factor XIII (F13A1), a
gene previously associated with the risk of venous thromboembo-
Figure 1. Diagram of the study design. Adipose tissue biopsies
from MZ twins discordant for BMI and from a collection of unrelated
individuals are analyzed by expression array. Contrasting the differences
in transcript profiles allows for the identification of putatively causative
genes effecting BMI. Subsequent GWA testing of SNP variants in the
identified genes allows for evaluation of genetic variation that may
predispose to obesity.
doi:10.1371/journal.pgen.1000976.g001
Author Summary
Obesity has a strong genetic component and an estimated
45%–85% of the variation in adult relative weight is
genetically determined. Many genes have recently been
identified in genome-wide association studies. The indi-
vidual effects of the identified genes, however, have been
very modest, and their identification required very large
sample sizes. New approaches are therefore needed to
uncover further genetic variants that contribute to the
development of obesity and related conditions. Much can
be learned from studying the expression of genes in
adipose tissue of obese and non-obese subjects, but it is
very difficult to distinguish which genes’ expression
differences represent reactions to obesity from those
related to causal processes. We studied monozygotic twin
pairs discordant for obesity and contrasted the gene
expression profiles of obese and lean co-twins (controlling
for genetic variation) to those from unrelated individuals
to try to discern the cause-and-effect relationships of the
identified changes in gene expression in fat. Testing the
identified genes in 21,000 individuals identified numerous
new genes with possible roles in the development of
obesity. Among the top findings was a gene involved in
blood coagulation (Factor XIIIA1), possibly linking obesity
with known complications including deep vein thrombo-
sis, heart attack, and stroke.
Transcriptomics and GWA in Hunt for Obesity Genes
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lism [13]. Altogether 7 SNPs in the F13A1 gene associated with
BMI in the 21,000 ENGAGE samples (Figure S2). Among the
other genes for which positive evidence of association (P,0.05)
could be shown were the sialyltransferase ST3GAL6, ribonuclease
4 (RNASE4), peroxiredoxin 6 (PRDX6), SH3 domain binding
glutamic acid-rich protein (SH3BGR), the influenza virus NS1A
binding protein (IVNS2ABP), the apoptosis antagonizing transcrip-
tion factor (AATF), transmembrane protein 101 (TMEM101) as
well as some novel transcripts with no known functions.
While the potential ‘‘reactive’’ genes did not deviate significantly
from the expected uniform distribution, the top 4 SNPs were of
some interest, as they were all located in the URB gene
(upregulated in bombesin receptor subtype 3 knockout mouse),
recently implicated as having a role in human obesity [14]. The
best P-value was obtained for intronic SNP rs9870432 (P= 0.001)
(Table 3). The association signal for URB was coming solely from
the women in the analysis, suggesting a possible gender-specific
role for this gene in influencing obesity and BMI.
F13A1 association with BMI replicates in GenMets study
In order to assess whether any of the associations observed in
the large ENGAGE sample were replicable, we utilized a smaller
available GWA study sample, namely the GenMets study - a case/
control study with ,2,000 individuals designed to investigate the
genetics of metabolic syndrome. The top-hit among the putatively
causative genes was again a SNP in the F13A1 gene (rs714408
P= 0.002) (Table S2). A meta-analysis of the two combined study
samples (N,23,000) increased the significance of this F13A1 SNP
to P= 0.0004). In this replication dataset the effect size of this
rs714408 variant on BMI was 20.2519 (60.1472) BMI units per
G allele carried. This equates to 0.14% of the variance in BMI. No
other genes implicated in the ENGAGE study replicated in this
Table 1. Relationship between adipose tissue gene expression and BMI for the putative causative genes among 77 unrelated
subjects (Pearsonian correlation and associated P-value), fold change, and P-value for the intrapair difference in gene expression
between obese and lean members of obesity discordant MZ pairs.
Unrelated subjects Discordant MZ twin pairs
Gene symbol
Affymetrix
probe-ID
Pearson
Correlation P-valuea
Obese/Lean
Expressionb P-valuec
SAP30BP 217965_s_at 20.51 9.9961025 1.00 0.56
MRPL9 209609_s_at 20.43 9.5761025 0.89 0.72
C20orf198 226149_at 20.35 9.2661025 0.93 0.45
IVNS1ABP 206245_s_at 0.46 8.8661025 1.24 0.08
SPSB3 46256_at 20.52 8.3261025 0.93 0.06
SART1 200051_at 20.34 8.2961025 1.01 0.83
ST3GAL6 210942_s_at 20.52 8.2761025 0.77 0.05
FAHD2A 222056_s_at 20.41 8.0561025 0.97 0.53
mRNA AK125162 231040_at 20.42 7.9561025 0.83 0.85
SH3BGR 204979_s_at 0.32 5.061025 1.13 0.11
NPY1R 205440_s_at 0.42 5.061025 1.15 0.14
EIF2B4 209429_x_at 20.48 4.8361025 1.07 0.62
EIF4EBP1 221539_at 20.54 4.5561025 0.82 0.08
AATF 209165_at 20.46 4.2661025 1.03 0.44
PRDX6 200844_s_at 20.48 3.3961025 0.93 0.18
SH3BGRL 201312_s_at 0.38 3.3361025 1.12 0.18
PCBD1 203557_s_at 20.56 3.161025 0.88 0.05
PRSS23 226279_at 0.33 2.7861025 1.11 0.07
BC007882 225657_at 20.28 2.7261025 0.96 0.67
ST3GAL6 213355_at 20.47 2.4861025 0.97 0.24
TMEM101 225004_at 20.36 1.7961025 0.96 0.11
F13A1 203305_at 0.41 9.5961026 1.13 0.11
TRAP1 201391_at 20.38 6.5361026 0.98 0.43
CRY2 212695_at 20.41 5.3561026 0.92 0.22
PPIE 210502_s_at 20.6 4.961026 0.97 0.54
C16orf62 225772_s_at 20.43 4.961026 0.83 0.06
RNASE4 213397_x_at 20.44 2.6861026 0.86 0.09
HADHA 208630_at 20.5 2.561026 1.03 0.35
Table has been sorted according to the P-value of the Pearson correlation.
aP-value for the Pearson correlation between BMI and gene expression in the set of 77 unrelated individuals.
bMedian fold difference in gene expression between the obese and lean co-twins. Values greater than 1.00 represent a higher expression level in the obese twin.
cP-value for non-parametric Welch t-test of gene expression between lean and obese co-twins of obesity discordant pairs.
doi:10.1371/journal.pgen.1000976.t001
Transcriptomics and GWA in Hunt for Obesity Genes
PLoS Genetics | www.plosgenetics.org 4 June 2010 | Volume 6 | Issue 6 | e1000976
smaller GenMets study sample, but the Q-Q plots bore the same
distinct differences as in Figure 2 with the putatively causal genes
outperforming the reactive genes (Figure S3). Among the reactive
genes, the URB variants associated with BMI in the ENGAGE
sample did not replicate in the GenMets study (best P= 0.46).
Discussion
While BMI is a highly heritable and much investigated trait in
humans, the success in identifying common predisposing genetic
variants has been relatively modest with until very recently, only two
solidly established gene findings to date, namely the FTO [3] and
MC4R [4] genes, each explaining only a small fraction of the
variance. The newest study identifying 6 additional obesity pre-
disposing variants in combination with FTO and MC4R explained
only 0.84% of the variance in BMI. While highlighting the complex
genetic and environmental background of obesity, this realization also
calls for novel designs in order to identify the remaining genes, each
arguably with increasingly more modest effect sizes, or having
characteristics that are not captured by the current generation of
SNP-chips. Utilizing a unique experiment of nature, namely
monozygotic twin pairs discordant for obesity and contrasting the
obese/lean co-twin differences in expression profiles in adipose tissue
with those from a collection of unrelated individuals, we were able to
circumvent some of the difficulties experienced by other studies and
infer putative causality of the observed expression changes in relation
to obesity. Testing for association in a large collection of GWA data
from European population cohorts (N = 21,000) we were able to
illustrate the power of this data mining scheme in uncovering novel
genetic variants associated with complex human traits like BMI.
In addition to genetic variation, the expression levels of genes, as
measured by appropriate microarrays, can be affected by several
factors including environmental variation, epigenetic modifica-
tions as well as by experimental conditions of in vitro cell lines.
Using monozygotic twin pairs discordant for obesity in our
experiment allowed for controlling for many of these factors, like
gender, age, early developmental environment as well as cohort-
effects. Being able to designate the differentially expressed
transcripts as reactive to the obesity allowed for the identification
in the unrelated sample set of transcripts with a putatively
causative role in effecting human obesity. SNP variants in the
genes designated as ‘‘causative’’ based on the MZ data performed
considerably better in the test for association with BMI than the
variants in the reactive genes, as evident in Figure 2.
A total of seven BMI associated SNP variants, including the top
SNP of the study were located in the F13A1 gene. Multiple F13A1
SNPs were also associated with BMI in the replication GWA
cohort, with the strongest evidence for association in the final
Figure 2. Q-Q plot comparing the distribution of P-values for the causative and reactive gene sets. SNP variants in the reactive genes are
marked by ‘‘x’’ while SNP variants in the putatively causative genes are marked with open circles. Line y = x represents the expected distribution of P-
values, following the uniform distribution.
doi:10.1371/journal.pgen.1000976.g002
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meta-analysis for SNP rs714408 (P= 0.0004). In our data set,
F13A1 transcript levels were also significantly associated with BMI
(Pearson correlation 0.41, P-value 9.661026) among the samples
from unrelated individuals. F13A1, coded for by a 177 kb gene in
chromosome 6p25.1 is a subunit of coagulation factor XIII, the
last zymogen to become activated in the blood coagulation cascade
and responsible for forming the crosslinks between fibrin molecules
that stabilize a clot [15]. A common V34L (rs5985) variant in
F13A1 has previously been associated with venous thromboem-
bolism, and supported by a recent large meta-analysis [13]. The
V34L variant was genotyped in this study, but failed to associate
with BMI directly in the ENGAGE set (P= 0.70). In light of this, it
does not seem like the V34L polymorphisms is the one underlying
the BMI association observed here, neither do we believe to
have captured the functional F13A1 variant itself. The linkage
disequilibrium between the V34L polymorphism and the rs714408
variant here identified is R2 = 0.142. The polymorphism(s) may
influence F13A1 in several ways by either modulating its
expression in the cells, by effecting its stability, or by changing
its activity in the circulation, as has been shown to be the mode of
action of the V34L polymorphism [16]. Further genotyping,
sequencing and functional analyses are required to elucidate the
functionality of the polymorphisms here identified. Aside from a
report describing a correlation of F13A1 expression with liver fat in
humans [17], this is to our knowledge the first instance where
F13A1 has been implicated in obesity. Given that obesity is well
known to predispose to the development of deep vein thromboses
and it is considered a chronic prothrombic state [16], these
observations may open new avenues for studying the link between
obesity and thrombosis. This may also help account for the
increased risk of cardiovascular disease in obese subjects.
Circumstantial evidence from a number of other studies lends
support for the possible role in obesity of several other genes
identified in the present study. The second best association with
BMI was for SNP rs865474 located in the gene ST3GAL6, coding
for a sialyltransferase. While no known link with obesity exists for
this gene, a previous study found its expression to be highly
variable and much more highly correlated between related
individuals in lymphoblastoid cell lines, suggesting that the
expression of this gene is under strong genetic control [18]. Our
results in the MZ twins agree with this finding and given the strong
correlation of the transcript with obesity in the unrelated
individuals (Pearson correlation 20.47, P= 2.4861025), this
makes ST3GAL6 a potentially interesting new candidate. The third
associating gene RNASE4 is a ribonuclease previously been shown to
be upregulated in adipose tissue of women following a low calorie
diet [19] and to be markedly increased after a 24 hour treatment
with cortisol [20]. In mice RNASE4 has been shown to be regulated
in the liver by dietary fat [21]. PRDX6, an antioxidant enzyme with
Ca-independent phospholipase A2 activity [22], was identified in a
recent study as a possible candidate gene underlying a novel obesity
locus on chromosome 1q24 in an isolated population of Cilento
[23]. The expression of SH3BGR was previously reported to be
downregulated in adipose tissue following weight reduction [24], a
finding consistent with the positive correlation of transcript levels
with BMI identified here (Pearson correlation 0.32, P= 5.061025).
Table 2. SNPs associating with BMI among the putatively causative genes in the ENGAGE consortium GWA sample.
Gene name MAF SNP N P-value women P-value men Overall P-value
F13A1 0.252 rs2274393 20,812 0.0084 0.1413 0.0030
ST3GAL6 0.463 rs865474 20,789 0.0571 0.0350 0.0050
F13A1 0.433 rs406238 20,782 0.0077 0.2417 0.0051
ST3GAL6 0.294 rs7628381 20,795 0.0266 0.1016 0.0059
RNASE4 0.269 rs3094 20,718 0.0021 0.6363 0.0074
C20orf198 0.156 rs1739652 4,584 0.0599 0.0599 0.0078
F13A1 0.152 rs11243069 20,805 0.0095 0.3712 0.0097
F13A1 0.220 rs9504743 20,806 0.0991 0.0414 0.0103
C16orf62 0.337 rs3782323 20,812 0.0616 0.0782 0.0104
PRDX8 0.262 rs6675929 20,797 0.0287 0.1753 0.0107
SH3BGR 0.234 rs2837035 20,806 0.0338 0.1876 0.0133
IVNS1ABP 0.433 rs1889976 20,807 0.0825 0.0876 0.0152
SH3BGRL 0.261 rs5959087 20,814 0.0741 0.1159 0.0173
SH3BGRL 0.262 rs12389790 20,777 0.0816 0.1122 0.0185
SPSB3 0.176 rs17559 16,029 0.0022 0.9365 0.0189
F13A1 0.266 rs9328347 20,808 0.1760 0.0474 0.0211
F13A1 0.347 rs387528 4,572 0.1031 0.1031 0.0212
F13A1 0.185 rs3024443 20,813 0.2437 0.0271 0.0216
AATF 0.214 rs11871099 20,803 0.1250 0.0825 0.0223
AATF 0.342 rs1564796 20,781 0.1268 0.0869 0.0233
IVNS1ABP 0.431 rs10911707 4,574 0.1323 0.1323 0.0333
TMEM101 0.432 rs1618809 20,778 0.1937 0.1183 0.0458
EIF4EBP1 0.223 rs6605631 4,584 0.1633 0.1633 0.0486
Table has been sorted according to the overall P-value.
MAF: minor allele frequency.
doi:10.1371/journal.pgen.1000976.t002
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An interesting candidate for obesity is IVNS1ABP (influenza virus
NS1A binding protein). While it has no known function with a
relation to obesity, a recent study of Oceanian population genetics
utilizing genome-wide SNP analyses identified the IVNS1ABP gene
as having undergone a selective sweep in the Oceanian population
[25]. Among other such genes identified in the study were the
VLDL-receptor and other lipid metabolism related genes, suggest-
ing that IVNS1ABP may represent just the kind of obesity
predisposing thrifty genes that have been hypothesized to be
enriched in the Oceanian populations with a well known current
epidemic of obesity and type 2 diabetes in conjunction with the
westernization of their diets and lifestyle. Another very plausible
candidate identified is the neuropeptide Y receptor 1 (NPY1R), a
receptor for a neuropeptide exhibiting a diverse range of physiologic
activities including effects on food intake [26].
While a whole number of genes had been filtered out from the
analyses as being clearly reacting to the obesity, there is no reason to
believe that they too could not contain variants that effect the
development of obesity. Genes that are designated as ‘‘reactive’’, but
still associate with obesity may be ones whose transcript levels are
affected by the developing obesity but that concurrently harbour
variants predisposing an individual to weight gain. In fact, the top
result (top 4 SNPs) among the genes identified as reactive, was URB,
a gene linked with obesity in mice [27] and recently implicated as
having a role in obesity in humans [14]. Our results here support a
gender specific role for SNP variants in URB in the development of
obesity. A few of the transcripts designated as ‘‘causative’’ also
approach nominal significance in regards to correlation with BMI
(Table 1), supporting the notion that some genes could eventually be
classified as both ‘‘causative’’ and ‘‘reactive’’.
The power of this study lies in the availability of the obesity
discordant monozygotic twins that enable the dissection of cause
and effect relationships between gene expression and obesity. A
similar approach could be utilized for many other complex traits
where discordant MZ twins and relevant tissue biopsies are
available, for example muscle biopsies from pairs discordant for
physical activity. Such collections of twins are admittedly rare, but
other approaches (animal clones exposed to different environ-
ments, human subjects that have gained or lost significant amounts
of weight) can approximate the experimental set up applied here.
The most recent GWA studies on obesity give considerable
hope that additional variants, each explaining in the range of 0.1%
of the variance will be identified in new, large scale GWA studies
utilizing tens of thousands of samples [5,7]. However, novel
integrative methods as described here are called for in order
to uncover the remaining variants. Such alternative designs,
combined with comprehensive sequencing of candidate genes and
loci, should give us a clearer picture of the allelic architecture and
help to discern the relative contributions of rare and common
variants to human obesity.
Materials and Methods
Study participants for the adipose tissue biopsies
Adipose tissue biopsies from two study samples originating from
the Finnish population were used. Both studies were performed
according to the principles of the Helsinki Declaration.
The twins from discordant pairs were recruited from a
population-based longitudinal study of five consecutive birth
cohorts (1975–1979) of twins, their siblings and parents
Table 3. SNPs associating with BMI among the reactive genes in the ENGAGE consortium GWA sample.
Gene name MAF SNP N P-value women P-value men Overall P-value
URB 0.457 rs9870432 20,574 0.0008 0.2973 0.0012
URB 0.314 rs6807798 20,659 0.0010 0.5546 0.0036
URB 0.384 rs10511316 20,644 0.0015 0.5113 0.0040
URB 0.372 rs2279531 20,613 0.0095 0.4464 0.0130
FLJ45244 0.148 rs3814816 20,437 0.1010 0.0631 0.0147
C12orf30 0.160 rs7297415 20,657 0.0856 0.1071 0.0189
PALLD 0.467 rs7670597 20,654 0.6463 0.0028 0.0249
CIDEA 0.376 rs6505744 20,658 0.1039 0.1397 0.0282
DAPK2 0.024 rs2034099 4,427 0.0019 0.8398 0.0293
MRC1 0.089 rs537085 4,407 0.2544 0.0531 0.0304
ABCC1 0.431 rs3887893 20,657 0.0749 0.2300 0.0323
ADAM12 0.288 rs1459709 20,665 0.1430 0.1125 0.0326
CCL2 0.322 rs991804 20,666 0.1117 0.1547 0.0329
ADAM12 0.493 rs1278377 20,654 0.0127 0.7924 0.0363
CLMN 0.375 rs12894609 20,650 0.0696 0.2778 0.0364
PALLD 0.470 rs6852874 20,311 0.1212 0.1719 0.0390
CCL2 0.388 rs4795893 20,661 0.0201 0.6731 0.0391
ABCC1 0.131 rs16967126 20,653 0.6589 0.0058 0.0397
ABCC1 0.167 rs152029 20,658 0.0362 0.5482 0.0443
PALLD 0.429 rs17542430 20,623 0.4509 0.0274 0.0471
CPVL 0.194 rs245857 20,587 0.3262 0.0525 0.0472
Table has been sorted according to the overall P-value.
MAF: minor allele frequency.
doi:10.1371/journal.pgen.1000976.t003
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(n = 2,453 families), identified through the national population
registry of Finland [28]. The twins selected for this study
represented the top 5% most obesity-discordant MZ twin pairs
(one co-twin not obese [BMI,25 kg/m2], and the other one obese
[BMI,30 kg/m2]), with no significant height differences (,3 cm)
or chronic illness. Of the 18 pairs thus identified, 13 pairs
participated in the adipose tissue biopsy. The study subjects have
been previously thoroughly described [11]. The protocol was
approved by the Ethical Committee of the Helsinki University
Central Hospital.
The unrelated study subjects were recruited as a part of the
European Multicenter Study on Familial Dyslipidemias in patients
with Premature Coronary Heart Disease (EUFAM) and consisted
of both healthy and affected individuals. The collection of subjects
has been described earlier [29,30]. The Ethical Committee of the
Department of Medicine, Helsinki University Central Hospital
approved the study.
All fat biopsies were collected under local anesthetic by a needle
aspiration of periumbilical subcutaneous fat, immediately frozen in
liquid nitrogen and stored at 280uC for later extraction of total
RNA using the RNeasy Lipid Mini Kit (Qiagen) according to
manufacturer’s instructions. Quality of RNA was analyzed using
the 2100 Bioanalyzer platform (Agilent Technologies).
Gene expression arrays
Two micrograms of total RNA were treated according to
conventional Affymetrix eukaryotic RNA labeling protocols
(Affymetrix, Santa Clara, CA). Fifteen micrograms of biotin
labeled cRNA was fragmented according to Affymetrix eukaryotic
sample protocol. Hybridization, staining and washing of the
Affymetrix U133 Plus 2.0 chips were performed using the
Affymetrics Fluidics Station 450 and Hybridization oven 640
under standard conditions. Prior to analysis, raw expression data
were normalized using the GCRMA algorithm, separately for the
MZ twin and non-related individuals. Analysis of the adipose
tissue expression data was done using the GeneSpring GX 7.3
software (Agilent Technologies).
Identifying the ‘‘reactive’’ versus ‘‘causative’’ transcripts
In order to include in the expression analyses only those probes
with reliably high signal, the expression data was first filtered
according to expression level so that only probes with expression
value$50 in at least K of the samples were included. Of the
,54,000 probesets available on the array 17,026 (,31%) passed
the filtering and were considered for analysis. Given the unique
set-up involving MZ twins, following standard GC-RMA normal-
ization of the expression signals, we next performed a ‘‘co-twin
normalization’’ procedure which involved dividing the obese
twin’s expression values with those of the non-obese co-twin in
order to correct for the identical genetic background (and by
definition also for gender and age). Using a liberal threshold for
significance (non-parametric Welch t-test P,0.05) we identified
2,674 transcripts differentially regulated in the adipose tissue of the
obese twins.
Next, in a data set consisting of adipose tissue samples from 77
unrelated individuals, using stringent criteria (Pearson correlation
P,1024) we identified 84 BMI correlated transcripts. Of these, 56
were shared with those identified in MZ study samples and
designated as ‘‘reactive’’. The remaining 28 transcripts encoded 27
unique genes that, while strongly correlated with BMI, were not
differentially regulated in the discordant MZ twins and as such
were candidates for being related to causal processes.
For the twin samples a liberal threshold was chosen in order to
avoid unintentionally designating them as ‘‘causative’’. This,
contrasting with the stringent criteria for significance applied for
the sample of unrelated individuals was done in order to avoid
false-positives in the last stage of filtering.
Meta-analysis of GWA data
For the genes identified through the expression profiling as
being either ‘‘causative’’ or ‘‘reactive’’, we retrieved all the
genotyped SNPs located in the coding sequence positions
61 kb, as annotated in the UCSC genome browser (March
2006 build). Altogether 197 SNPs in these genes were tested for
association with BMI in the large set of ENGAGE cross-sectional
population cohorts from populations of European origin
(N = 21,000). All available SNPs were similarly retrieved for the
49 genes (represented by 56 Affymetrix probes) that were
designated as ‘‘reactive’’. One of the genes was X-chromosomal
for which no genotypes were available. This resulting set of 48
genes was used as the control gene set against which we compared
the association findings with the genes designated putatively
causative. Within each of the 16 ENGAGE cohorts logarithmized
BMI measures were stratified by sex and in each of the stratum
outcomes were adjusted for age using linear regression model. The
residuals resulting from these models were then standardized and
used as outcome measures in the association analyses. Association
analyses were performed with linear regression assuming additive
mode of inheritance. These cohort specific results were combined
into a fixed effects meta-analysis with reciprocal weighting on the
square of standard errors of the effect size estimates.
Replication GWA study sample: GenMets
As a replication study sample we utilized the GenMets study
collected from the Finnish population for an investigation of the
genetics of metabolic syndrome. GenMets individuals were
sampled from a Finnish population-based Health 2000 study.
Details of the Health 2000 study and phenotype measurements
have been reported earlier [31]. The sample consisted of 919
individuals with non-diabetic metabolic syndrome, and 932
individuals without the metabolic syndrome, as defined by the
International Diabetes Federation [32]. The individuals were
genotyped using Illumina HumanHap 610 K chip and imputed
using the Hapmap 1+2 CEU reference data.
Statistical analysis
GCRMA normalized gene expression values in the sample of
unrelated individuals were evaluated for correlation with BMI
using the Pearson correlation as implemented in SPSS 11.0 for
Windows (SPSS Inc., Chicago, IL, USA). A P-value of ,1024 was
considered significant. Following co-twin normalization, differen-
tial expression of transcripts between the BMI discordant MZ twin
pairs was evaluated in Gene Spring GX 7.3 software (Agilent
Technologies) by the non-parametric Welch t-test with P,0.05
considered significant for further analysis. The Pearson X2 test of
categorized P-values was used to test for deviation of the
distribution of observed P-values from the uniform distribution.
In GenMets GWA analyses logarithmized BMI measures were
adjusted for sex, age and metabolic syndrome affection status using
linear regression model Metabolic syndrome status was used as a
covariate in the linear model to minimize the effect of the study
design. The main component behind the metabolic syndrome
definition used in GenMets is waist circumference, although
correlated with BMI, it may have a different genetic background
from BMI. However, by adjusting we may run into over-adjusting
and losing some statistical power. The residuals resulting from
these models were standardized and used as outcomes as in
Transcriptomics and GWA in Hunt for Obesity Genes
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ENGAGE analyses, Association analysis was conducted using
PLINK [33] option linear.
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